Appendix B. Sources of Evidence

Appendix B. Sources of Evidence

The following documentation and opinion was made available to the Appraisals Committee:

a. Assessment Report:

  • Prepared by The NHS Centre for Reviews and Dissemination (A rapid and systematic review of the clinical effectiveness and cost-effectiveness of trastuzumab and vinorelbine for breast cancer, February 2001)

  • Prepared by The NHS Centre for Reviews and Dissemination (A rapid and systematic review of the clinical effectiveness and cost-effectiveness of trastuzumab for breast cancer, October 2001)

b. Manufacturer/sponsor submissions:

  • Roche

c. Professional/specialist group submissions from:

  • British Psychosocial Oncology Society

  • Imperial Cancer Research Fund

  • MRC Clinical Trials Unit

  • National Cancer Research Institute

  • Royal College of General Practitioners

  • Royal College of Pathologists

  • Royal College of Physicians

d. Patient group submissions from:

  • Breakthrough Breast Cancer, CancerBACUP and the UK Breast Cancer Coalition joint submission

  • Breast Cancer Care

  • Macmillan Cancer Relief

e. Other group submissions from:

  • Department of Health

  • National Assembly for Wales

f. External expert and patient advocate submissions from:

  • Professor Robert Coleman, Professor of Medical Oncology, Cancer Research Centre,Weston Park Hospital, University of Sheffield

  • Bernie Gardiner, Information Nurse Specialist, Breast Cancer Care

  • Margaret King, Vice Chair, UK Breast Cancer Coalition